Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897925 | 0.83 | TACR1 (0.59) | TACR1 | |
| SCHEMBL7390057 | 0.83 | MTOR (0.55) | TACR1 | |
| SCHEMBL12435665 | 0.83 | TACR1 (0.57) | TACR1 | |
| SCHEMBL12513145 | 0.80 | TACR1 (0.55) | TACR1 | |
| SCHEMBL2935441 | 0.78 | CACNA1G (0.55) | TACR1 | |
| SCHEMBL19948809 | 0.76 | TACR1 (0.53) | TACR1 | |
| SCHEMBL13451382 | 0.75 | TACR1 (0.49) | TACR1 | |
| SCHEMBL13178016 | 0.75 | TACR1 (0.61) | TACR1 | |
| SCHEMBL16085605 | 0.75 | TACR1 (0.49) | TACR1 | |
| SCHEMBL5428175 | 0.74 | TACR1 (0.52) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305159-A1 | CRYSTALLINE FORM OF PIPERIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-02 | — | — | US | disclosed |
| EP-1513814-B1 | NOVEL PIPERIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20090198052-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2022782-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE PIPERIDINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-02-11 | — | — | EP | disclosed |
| EP-1513814-A4 | NOVEL PIPERIDINE COMPOUND | TANABE SEIYAKU CO (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-20050239829-A1 | Novel piperidine compound | TANABE SEIYAKU CO. LTD. (JP) | 2005-10-27 | — | — | US | disclosed |
| EP-1513814-A1 | NOVEL PIPERIDINE COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003099787-A1 | NOVEL PIPERIDINE COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305159-A1 | CRYSTALLINE FORM OF PIPERIDINE COMPOUND | PML, H1-4, NPM1 | TACR1 2378/4885 |
| US-20050239829-A1 | Novel piperidine compound | EP300, BRD1, CBR3 | TACR1 379/4885 |
| US-20090198052-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS | SNCA, SYNJ1, KCNH2 | TACR1 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.